期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
P2Y6在心血管疾病中的研究进展
1
作者 张倩 胡庆华 《药学研究》 CAS 2021年第9期620-623,共4页
嘌呤能受体P2Y6是P2Y受体家族的成员,它具有典型的7次跨膜结构,属于G蛋白偶联受体家族。P2Y6R主要在内皮细胞(ECs)和平滑肌细胞(SMCs)的基质细胞上表达,而P2Y6R在心血管系统不同细胞或区域中的分布有助于其在心血管疾病(CVD)中发挥作用... 嘌呤能受体P2Y6是P2Y受体家族的成员,它具有典型的7次跨膜结构,属于G蛋白偶联受体家族。P2Y6R主要在内皮细胞(ECs)和平滑肌细胞(SMCs)的基质细胞上表达,而P2Y6R在心血管系统不同细胞或区域中的分布有助于其在心血管疾病(CVD)中发挥作用。这篇综述旨在概述P2Y6R在心血管疾病的发病机制中的作用,并介绍P2Y6R拮抗剂的最新进展。 展开更多
关键词 p2y6r 心血管疾病 分子机制 治疗靶点
下载PDF
Macrophage P2Y_(6)R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses
2
作者 Li Yin Enming Zhang +10 位作者 Tianqi Mao Yifan Zhu Shurui Ni Yehong Li Chunxiao Liu Yafei Fang Kexin Ni Yuhe Lu Huanqiu Li Mengze Zhou Qinghua Hu 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2024年第10期4360-4377,共18页
Purinergic signaling plays a causal role in the modulation of immune inflammatory response in the course of psoriasis,but its regulatory mechanism remains unclear.As a member of purinoceptors,P2Y_(6)R mainly distribut... Purinergic signaling plays a causal role in the modulation of immune inflammatory response in the course of psoriasis,but its regulatory mechanism remains unclear.As a member of purinoceptors,P2Y_(6)R mainly distributed in macrophages was significantly up-expressed in skin lesions from patients with psoriasis in the present study.Here,the severity of psoriasis was alleviated in imiquimod-treated mice with macrophages conditional knockout of P2Y_(6)R,while the cell-chat algorithm showed there was a correlation between macrophage P2Y_(6)R and Th1 cells mediated by IL-27.Mechanistically,P2Y_(6)R enhanced PLCβ/p-PKC/MAPK activation to induce IL-27 release dependently,which subsequently regulated the differentiation of Th1 cells,leading to erythematous and scaly plaques of psoriasis.Interestingly,we developed a novel P2Y_(6)R inhibitor FS-6,which bonds with the ARG266 side chain of P2Y_(6)R,exhibited remarkable anti-psoriasis effects targeting P2Y_(6)R.Our study provides insights into the role of P2Y_(6)R in the pathogenesis of psoriasis and suggests its potential as a target for the development of therapeutic interventions.A novel P2Y_(6)R inhibitor FS-6 could be developed as an anti-psoriasis drug candidate for the clinic. 展开更多
关键词 MACROPHAGES p2y6r PSORIASIS FS-6 IL-27
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部